

BioMmune Technologies Inc.
#4-3300 157A St Surrey BC V3S 2P2

For immediate release: Vancouver B.C. – September 24th, 2013

TSX.V: IMU

**BioMmune Technologies Inc. Announces the Appointment of Dr.
Karoly Nikolich to its Board Of Directors**

Vancouver, British Columbia, September 24th, 2013. BioMmune Technologies Inc., (TSXV: IMU) is pleased to announce the appointment of Dr. Karoly Nikolich to its Board of Directors.

Dr. Nikolich is a renowned biotechnology expert with an extensive track record within this industry. Highlights include: former head of the Neuroscience Program at Genentech Inc; Adjunct Professor, Neuroscience, USC, Los Angeles, CA; Vice President, Research, Lynx Therapeutics, Inc. Hayward, CA and Director (Supervisory Board) BASF-LYNX Bioscience AG, Heidelberg; former CEO, Amnestix, Inc., and Neurofluidics, Inc., Burlingame, CA; Executive Director, Neuroscience Institute at Stanford (NIS), Stanford University Medical School; Founder, Chief Executive Officer, and Director (Board member) AGY Therapeutics, Inc., South San Francisco, CA; and currently Dr. Nikolich is Founder and President of Circuit Therapeutics, Inc., and a consulting Professor at Stanford University Medical School. Along with an extensive professional history, Dr. Nikolich has been an author on over 120 scientific and review publications.

“We are thrilled to have Karoly join the BioMmune team,” said Rob Hutchison, Executive Chairman. “Karoly’s experience brings a tremendous dynamic to BioMmune and his guidance at the board level will help us in meeting our scientific and corporate objectives.”

“I’m very excited to be joining the BioMmune team and believe that the opportunities for BioMmune have great potential,” said Dr. Nikolich, “I’m looking forward to digging in and helping the team meet its objectives.”

Mr. Nikolich will receive 150,000 incentive stock options, exercisable at \$0.20 for 5 years from the date of grant, subject to the approval of the TSX Venture Exchange.

ABOUT BIOMMUNE

BioMmune Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. BioMmune is developing three technologies discovered at The University of British Columbia. They include, discovery of compounds that will be active in restoring immune-recognition of cancer cells resulting in the body’s immune system to eliminate cancer cells and a discovery relating to Calcium Channels, whose activities regulate the concentration of calcium (Ca) in different compartments in cells, which is very important for the activity of cells involved in the immune system to improve their ability to combat cancers, infections and also autoimmunities. Furthermore, the company is pursuing the modulation of CD74, a protein involved in the immune system and its ability to fight foreign antigens. Finding ways or compounds that regulate its activity will improve the immune system to combat infections,

cancers and autoimmune diseases. BioMmune trades on the TSX Venture Exchange under the symbol “IMU”.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for the therapeutic compounds to be developed based on our intellectual property, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

“Rob Hutchison”

Rob Hutchison, Executive Chairman and Director
(604)644.1232
rob@biommune.net

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”